case_images: PMC5557159_01
case_images: PMC5557159_02
case_images: Subject sweat rate as a function of glycopyrrolate dose. Both subjects showed decreased sweat rates with both 2 and 4 mg of glycopyrrolate.
case_images: 10.1177_2050313X17721601-fig1.jpg
case_images: PMC5557159_02_10.1177_2050313X17721601-fig1.jpg
case_images: fig1-2050313X17721601
case_images: Glycopyrrolate dose was non-significantly correlated with decreased sweat rate (r = -0.79, p = 0.06; Figure 1) and maximal core temperature (r = 0.60, p = 0.21; Figure 2). The patient with HH decreased his sweat rate from 4.4 L/h (53 mL/kg/h) with 0 mg glycopyrrolate to 2.0 L/h (24 mL/kg/h) and 1.8 L/h (22 mL/kg/h) with 2 and 4 mg of glycopyrrolate, respectively (Figure 1). This is in comparison to the control subject with a sweat rate of 2.0 L/h (26.7 mL/kg/h) with 0 mg of glycopyrrolate to 1.4 L/h (18.7 mL/kg/h) and 0.6 L/h (8.0 mL/kg/h) with 2 and 4 mg of glycopyrrolate, respectively (Figure 1).
case_images: Subject core temperature ( C) on the Y-axis as a function of time and dose of glycopyrrolate. Temperature increased significantly for both subjects with the 4 mg dose of glycopyrrolate and physical exertion.
case_images: 10.1177_2050313X17721601-fig2.jpg
case_images: PMC5557159_02_10.1177_2050313X17721601-fig2.jpg
case_images: fig2-2050313X17721601
case_images: Glycopyrrolate dose was non-significantly correlated with decreased sweat rate (r = -0.79, p = 0.06; Figure 1) and maximal core temperature (r = 0.60, p = 0.21; Figure 2). The patient with HH's core temperature was unchanged between the trials with 0 and 2 mg of glycopyrrolate (38.19 C and 37.96 C, respectively), but increased to 38.65 C with 4 mg glycopyrrolate (Figure 2). The control subject had a similar maximal core temperature response as he was unchanged with 0 and 2 mg of glycopyrrolate (38.43 C and 38.28 C, respectively), but increased to 39.27 C with 4 mg of glycopyrrolate (Figure 2).
case_images: Subject heart rate (beats per minute) as a function of time (minutes) and dose of glycopyrrolate. Maximum heart rate was not clinically different for each subject when comparing each individual subject across all three glycopyrrolate dosages.
case_images: 10.1177_2050313X17721601-fig3.jpg
case_images: PMC5557159_02_10.1177_2050313X17721601-fig3.jpg
case_images: fig3-2050313X17721601
case_images: Neither subject had a significant change in heart rate with 2 or 4 mg of glycopyrrolate compared to 0 mg of glycopyrrolate (Figure 3).